Antibiotic-associated diarrhea and pseudomembranous colitis: Are they less common with poorly absorbed antimicrobials?

Chemotherapy

Volumn 51, Issue SUPPL. 1, 2005, Pages 81-89

  Surawicz, Christina M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibiotic associated diarrhea; Clostridium difficile; Clostridium difficile associated diarrhea; Pseudomembranous colitis; Rifaximin

Indexed keywords

CEFTRIAXONE; CLINDAMYCIN; METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; SULTAMICILLIN; VANCOMYCIN;

ADD ON THERAPY; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BACTERIUM CULTURE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DIETARY FIBER; DISPOSABLE EQUIPMENT; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HYPERSENSITIVITY; ERADICATION THERAPY; FECES MICROFLORA; HAND WASHING; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTESTINE FLORA; KLEBSIELLA OXYTOCA; LACTOBACILLUS GASSERI; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; SACCHAROMYCES BOULARDII; TRAVELLER DIARRHEA; TREATMENT CONTRAINDICATION;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIALS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INTESTINAL ABSORPTION; LACTOBACILLUS; METRONIDAZOLE; PROBIOTICS; VANCOMYCIN;

EID: 18644384233     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081993     Document Type: Review

References (78)

1. Bergogne-Berezin E: Treatment and prevention of antibiotic associated diarrhea. Int J Antimicrob Agents 2000;16:521-526.
2. Bartlett JG: Antibiotic-associated diarrhea. Clin Infect Dis 1992;15:573-581.
3. McFarland LV: Diarrhea acquired in the hospital; in Giannella RA (ed): Acute Infectious Diarrhea. Philadelphia, W.B. Saunders, 1993, pp 563-577.
4. Znidi N, Ponce de Leon S, Oritz RM, et al: Hospital-acquired diarrhea in adults: A prospective case-controlled study in Mexico. Infect Control Hosp Epidemiol 1991;12:349-355.
5. Lima N, Guerrant RL, Kaiser DL, Germanson T, Farr BM: A retrospective cohort study of nosocomial diarrhea as a risk factor for nosocomial infection. J Infect Dis 1990;161:948-952.
6. Finney JMT: Gastro-enterostomy for cicatrizing ulcer of the pylorus. Johns Hopkins Med J 1893;4;53-55.
7. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G: Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii. A prospective study. Gastroenterology 1989;96:981-998.
8. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL: Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-448.
9. Winston DJ, Winston GH, Bruckner DA, Champlin RE: Beta-lactam antibiotic therapy in febrile granulocytopenic patietns. Ann Intern Med 1991;115:849-859.
10. McFarland LV, Stamm WE: Nosocomial Clostridium difficile infection (letter). N Engl J Med 1989;321:190.
11. Knobel H, Salvado M, Plass E, Orfila A, Llorach I, Diez A: Nosocomial epidemic outbreak of diarrhea from Clostridium difficile. Comparative study of diarrhea associated with the use of antibiotics (in Spanish). Med Clin (Barc) 1994;102:165-168.
12. Barbut F, Petits JC: Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001;7:405-410.
13. Buchner AM, Sonnenberg A: Medical diagnoses and procedures associated with Clostridium difficile colitis. Am J Gastroenterology 2001;96:766-772.
14. Levy DG, Stergachis A, McFarland LV, Van-Vorst K, Graham DJ, Johnson ES, Park B-J, Shatin D, Clouse JC, Elmer GW: Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther 2000;22:91-102.
15. Van der Waaij D: Colonization resistance of the digestive tract - mechanism and clinical consequences. Nahrung 1987;81:507-517.
16. Clausen MR, Bonnen H, Tvede M, Mortensen PB: Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea. Gastroenterology 1991;101:1497-1504.
17. Rao SS, Edwards CA, Austen CJ, Bruce C, Read NW: Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 1988;94:928-932.
18. Schultz AA, Ashby-Hughes B, Taylor R, Gillis DE, Willkins M: Effects of pectin on diarrhea in critically ill tube-fed patients receiving antibiotics. Am J Crit Care 2000;9:430-411.
19. Benoit R, Dorval D, Loulergue J, Bacq Y, Oliver JM, Audurier A, Metman EH: Post-antibiotic diarrheas: Role of Kiebsiella oxytoca (in French). Gastroenterol Clin Biol 1992;16:860-864.
20. Bellaiche G, Le Pennec MP, Coudat L, Ley G, Slama JL: Value of proctosigmoidoscopy with bacteriological culture of colonic biopsies in the etiological diagnosis of post-antibiotic acute diarrhea in adults. Prospective study in 24 patients. Pathol Biol 1997;45:70-715.
21. Gupta TP, Ehrinpreis MN: Candida-associated diarrhea in hospitalized patients. Gastroenterology 1990;98:780-785.
22. Danna PL, Urban C, Bellin E, Rahal JJ: Role of Candida in pathogenesis of antibiotic-associated diarrhoea in elderly inpatients. Lancet 1991;337:511-514.
23. Chaudhury A, Nath G, Shukla B, Panda S, Singh TB: Diarrhoea associated with Candida spp.: Incidence and seasonal variation. J Diarrhoeal Dis Res 1996;14:110-112.
24. Ponnuvel KM, Rajkumar R, Menon T, Sankaranarayanan VS: Role of Candida in indirect pathogenesis of antibiotic associated diarrhoea in infants. Mycopathologia 1996;135:145-147.
25. Forbes D, Ee L, Camer-Pesci P, Ward PB: Faecal Candida and diarrhoea. Arch Dis Child 2001;84:328-331.
26. Levine J, Dykoski RK, Janoff EN: Candida-associated diarrhea: A syndrome in search of credibility. Clin Infect Dis 1995;21:881-886.
27. Krause R, Schwab E, Bachhiesl D, Daxbock F, Wenisch C, Krejs GJ, Reisinger EC: Role of Candida in antibiotic-associated diarrhea. J Infect Dis 2001;184:1065-1069.
28. Hill MJ, Drasar BS: The normal colonic bacterial flora. Gut 1975;16:318-323.
29. Peach S, Fernandez F, Johnson K, Drasar S: The non-sporing anaerobic bacteria in human faeces. J Med Microbiol 1974;7:213-221.
30. Mette U, Werner H, Krasemann C, Ungerechts J: The effect of antimicrobial agents on human intestinal flora, with particular reference to Bacteroides species. Infection 1980;8(suppl 2):S215-S218.
31. Marr JJ, Sans MD, Tedesco FJ: Bacterial studies of clindamycin-associated colitis. A preliminary report. Gastroenterology 1975;69:362-358.
32. Bartlett JG, Condon RE, Gorbach SL, Clarke JS, Nichols RL, Ochi S: Veterans Administration Cooperative Study on Bowel Preparation for Elective Colorectal Operations: Impact of oral antibiotic regimen on colonic flora, wound irrigation cultures and bacteriology of septic complications. Ann Surg 1978;188:249-254.
33. Vergnes D, Moatti N, Monrozies X, Lazorthes F, Enjalbert L: Pre-operative colonic preparation using kanamycin and metronidazole: Qualitative and quantitative effects on the bacterial flora of the intestine. J Antimicrob Chemother 1980;6:709-716.
34. Krager L, Liljeqvist L, Malmborg AS, Nord CE, Pieper R: Effects of ampicillin plus sulbactam on bowel flora in patients undergoing colorectal surgery. Antimicrob Agents Chemother 1982;22:208-212.
35. Nord CE, Heimdahl A, Kager L, Malmborg AS: The impact of different antimicrobial agents on the normal gastrointestinal microflora of humans. Rev Infect Dis 1984;6(suppl 1):S270-S275.
36. Nord CE, Kager L, Philipson A, Stiernstedt G: Effect of impipenem/cilastatin on the colonic microflora. Rev Infect Dis 1985;7(suppl 3):S432-S434.
37. Mittermayer HW: Influence of temocillin on human bowel flora. Drugs 1985;29(suppl 5):43-48.
38. Sjovall J, Huitfeldt B, Magni L, Nord CE: Effect of beta-lactam prodrugs on human intestinal microflora. Scand J Infect Dis Suppl 1986;49:73-84.
39. Nord CE, Bergman T, Aase S: Impact of azlocillin on the colon microflora. Scand J Infect Dis 1986;18:163-166.
40. Van den Bogaard AE, Weidema WF, van Boven CP, van der Waay D: Recolonization and colonization resistance of the large bowel after three methods of preoperative preparation of the gastrointestinal tract for elective colorectal surgery. J Hyg (Lond) 1986;97:49-59.
41. Nord CE, Kager L, Malmborg AS: Effects of antimicrobial prophylaxis on colonization resistance. J Hosp Infect 1988;11(suppl A):259-264.
42. Wistrom J, Norrby SR, Myhre EB, Eriksson S, Granstrom G, Lagergren L, Englund G, Nord CE, Svenungsson B: Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: A prospective study. J Antimicrob Chemother 2001;47:43-50.
43. Silva M, Cornick NA, Gorbach SL: Suppression of colonic microflora by cefoperazone and evaluation of the drug as potential prophylaxis in bowel surgery. Antimicrob Agents Chemother 1989;33:835-848.
44. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM: Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998;128:989-995.
45. Welling GW, Meijer-Severs GJ, Helmus G, van Santen E, Tonk RH, de Vries-Hospers HG, van der Waaij D: The effect of ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract. Infection 1991;19:313-316.
46. Cavallaro V, Catania V, Bonaccorso R, Mazzone S, Seciale A, Di Marco R, Blandino G, Caccamo F: Effect of a broad-spectrum cephalosporin on the oral and intestinal microflora in patients undergoing colorectal surgery. J Chemother 1992;4:82-87.
47. Nelson DE, Auerbach SB, Baltch AL, Desjardin E, Beck-Sague C, Rheal C, Smith RP, Jarvis WR: Epidemic Clostridium difficile-associated diarrhea: Role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994;15:88-94.
48. Hecht JR, Olinger EJ: Clostridium difficile colitis secondary to intravenous vancomycin. Dig Dis Sci 1989;34:148-149.
49. Swabb EA, Sugerman A, Stern M: Oral bioavailability of the monobactam aztreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother 1983;23:548-550.
50. De Vries-Hospers HG, Welling GW, Swabb EA, Van der Waaij D: Selective decontamination of the digestive tract with aztreonam: A study of 10 healthy volunteers. J Infect Dis 1984;150:636-642.
51. DuPont HL, Ericsson CD, Mathewson JJ, de la Cabada FJ, Conrad DA: Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. JAMA 1992;267:1932-1935.
52. Ericsson CD, DuPont HL, Sullivan P, Galindo E, Evans DG, Evans DJ: Bicozamycin, a poorly absorbable antibiotic, effectively treats traveler's diarrhea. Ann Intern Med 1983;98:20-25.
53. Jiang ZD, Ke S, Palazzini E, Riopel L, DuPont H: In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-2206.
54. Steffen R: Rifaximin: A nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea. J Travel Med 2001;8(suppl 2):S34-S39.
55. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC: In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000;46:253-266.
56. Bresadola F, Intini S, Anania G, Noce L, Cedolini C, DeAnna D, Ferrieri A: Chemotherapeutic prophylaxis in the preparation of the large intestine for surgical interventions: Rifaximin p.o. vs. cephalosporin i.v. (in Italian). Ann Ital Chir 1992;63:201-207.
57. Gillis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467-484.
58. McFarland LV: Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998;16:292-307.
59. Crabtree TD, Pelletier SJ, Gleason TG, Pruett TL, Sawyer RG: Clinical characteristics and antibiotic utilization in surgical patients with Clostridium difficile-associated diarrhea. Am Surg 1999;65:507-511.
60. Hogenauer C, Hammer HF, Krejs GJ, Reisinger EC: Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998;27:702-710.
61. Wilcox MH, Howe R: Diarrhoea caused by Clostridium difficile: Response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995;36:673-679.
62. Wenisch C, Parschalk B, Hasenhundl M, Hirschel AM, Graninger W: Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22:813-818.
63. DuPont HL, Ericsson CD, Mathewson JJ, Plalzzini E, DuPont MW, Jiang ZD, Mosavi A, de la Cabada FJ: Rifaximin: A nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 1998;59:708-714.
64. Ripa S, Mignini F, Prenna M, Falconi E: In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp Clin Res 1987;13:483-488.
65. Boero M, Berti E, Morgando A, et al: Terapia della colite da Clostridium difficile: Risultati di uno studio randomizzato aperto rifaximina vs. vancomicina. Microbiol Med 1990;5:74-77.
66. McFarland LV, Surawicz CM, Elmer GE: Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease cases. Am J Gastroenterol 2002;97:1769-1775.
67. Fuller R: Probiotics in human medicine. Gut 1991;32:439-442.
68. Reid G: Probiotics in the treatment of diarrheal diseases. Curr Infect Dis Rep 2000;2:78.
69. Gotz V, Romankiewicz JA, Moss J, Murray HW: Prophylaxis against ampicillin-associated diarrhea with a Lactobacilllts preparation. Am J Hosp Pharm 1979;36:754-757.
70. Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF: A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP 1990;24:382-384.
71. Clements ML, Levine MM, Ristaino PA, Daya VE, Hughes TP: Exogenous lactobacilli fed to man - their fate and ability to prevent diarrehal disease. Prog Food Nutr Sci 1983;7:29-37.
72. Siitonen S, Vapatalo H, Salminen S, Gordin A, Saxelin M, Wikberg R, Kirkkola AL: Effect of Lactobacillus GG yoghurt in prevention of antibiotic assoicated diarrhoea. Ann Med 1990;22:57-59.
73. Contardi I: Batterioterapia orale quale prevenzione della diarrea da antibiotici en età pediatrica. Clin Ter 1991;136:409-413.
74. Arvola T, Laiho K, Torkkeli S, Mykkanen H, Salminen S, Maunula L, Isolauri E: Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study. Pediatrics 1999;104:e64.
75. Armuzzi A, Cremonini F, Ojetti V, Bartolozzi F, Canducci F, Candelli M, Santarelli L, Cammarota G, De Lorenzo A, Pola P, Gasbarrini G, Gasbarrini A: Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: A pilot study. Digestion 2001;63:1-7.
76. Borgia M, Sepe N, Brancato V, Borgia R: A controlled clinical study on Streptococcus faecium preparation for the prevention of side reactions during long-term treatments. Curr Ther Res 1982;31:265-271.
77. Wunderlich PF, Braun L, Fumagalli I, D'Apuzzo V, Heim F, Karly M, Lodi R, Politta G, Vonbank F, Zeltner L: Double-blind report on the efficacy of lactic-acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res 1989;17:333-338.
78. Breves G, Faul K, Schroder B, Holst H, Caspary WF, Stein J: Application of the colon-simulation technique for studying the effects of Saccharomyces boulardii on basic parameters of porcine cecal microbial metabolism disturbed by clindamycin. Digestion 2000;61:193-200.